A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study

Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2022-04, Vol.15 (1), p.40-40, Article 40
Main Authors: Tsubata, Yukari, Hotta, Takamasa, Hamai, Kosuke, Furuya, Naoki, Yokoyama, Toshihide, Saito, Ryota, Nakamura, Atsushi, Masuda, Takeshi, Hamaguchi, Megumi, Kuyama, Shoichi, Honda, Ryoichi, Senoo, Tadashi, Nakanishi, Masamoto, Yamasaki, Masahiro, Ishikawa, Nobuhisa, Fujitaka, Kazunori, Kubota, Tetsuya, Kobayashi, Kunihiko, Isobe, Takeshi
Format: Article
Language:English
Subjects:
Adenocarcinoma
Asymptomatic
Blood pressure
Cancer
Cancer therapies
Care and treatment
Cell number
Chemotherapy
Deep vein thrombosis
Female
Health aspects
Humans
Letter to the Editor
Lung cancer
Lung Neoplasms - complications
Lymphocytes
Multivariate analysis
Oncology, Experimental
Patients
Prognosis
Prospective Studies
Prothrombin
Prothrombin fragment 1 + 2
Pulmonary thromboembolism
Risk Assessment
Risk Factors
Risk-assessment model
Thrombin
Thromboembolism
Thrombosis
Venous Thromboembolism - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-022-01259-7